Mesoblast Limited (MESO) News
Filter MESO News Items
MESO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MESO News Highlights
- MESO's 30 day story count now stands at 12.
- Over the past 7 days, the trend for MESO's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- ARDS, AGE and HR are the most mentioned tickers in articles about MESO.
Latest MESO News From Around the Web
Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSMesoblast (MESO) announces the 60 day results from remestemcel-L trial in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome ((ARDS)).Remestemcel-L reduced mortality through day 60 by 46% in the pre-specified group below age 65, but not in patients 65 or older.Mortality rate was reduced by 75% and days... |
5 Top Stock Gainers for Friday: Overstock, Aon, Cryolife - TheStreetOverstock.com, Aon, Cryolife, AstraZeneca, Cryolife and Mesoblast are five stock gainers for Friday. |
Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory DistressMesoblast Limited (NASDAQ: MESO ) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS), which had been halted after the third interim analysis, as previously announced. The trial enrolled 222 mechanically ventilated COVID-19 patients. Remestemcel-L reduced mortality by 46% through day 60 in the pre-specified population of 123 treated patients under age … Full story available on Benzinga.com |
Why Mesoblast Limited Stock Is Jumping TodayShares of Mesoblast Limited (NASDAQ: MESO) are rising sharply on Friday after the company reported positive results from a clinical trial for one of its pipeline candidates, remestemcel-L. The biotech's stock was up 7.3% as of 3:22 p.m. EDT, after soaring by as much as 24.5% earlier in today's trading session. In a clinical trial investigating the efficacy of remestemcel-L in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS), the medicine was shown to reduce mortality by 46% in patients under the age of 65 through day 60, but not in those aged 65 and older. Mesoblast CEO Silviu Itescu said, "Reduction in mortality in mechanically ventilated patients under 65 years old remains a critical unmet need since as many as 72% of currentl... |
Appendix 4C Quarterly Activity ReportMesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021. “We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ventilation due to COVID-19. These showed that remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old, particularly when used with dexamethasone as part of standard of care. This has the potential to make a substantial impact in outcomes for this cr... |
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For ArdelyxHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Bi... |
Mesoblast's (ASX:MSB) Stock Price Has Reduced 46% In The Past YearPassive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While... |
Mesoblast Operational Highlights and Upcoming MilestonesNEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Company’s recent operational highlights, as well as upcoming milestones. Operational highlights included: Successful completion of US$110 million private placement, with pro-forma cash balance at December 31, 2020, of US$187.5 millionPrivate placement was led by US investor group SurgCenter Development (SurgCenter), one of the largest private operators of ambulatory surgical centers (ASC) in the US specializing in spine, orthopaedic and total joint proceduresAppointment of Philip J. Facchina, Chief Strategy Officer of SurgCenter, to the Mesoblast Board of DirectorsResults from Phase 3 trial of r... |
Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast BoardNEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip J. Facchina has joined its Board of Directors. Mr Facchina is Chief Strategy Officer of SurgCenter Development (SurgCenter), one of the largest private operators of ambulatory surgical centers (ASC) in the US specializing in spine, orthopaedic and total joint procedures. The principals of SurgCenter were the lead investors in Mesoblast’s successful US$110 million private placement, completed earlier this month. Mr Facchina brings more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr Facchina has been Ch... |